Current bladder cancer tests: Unnecessary or beneficial?

Michael A. Simon, Vinata B Lokeshwar, Mark S. Soloway

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.

Original languageEnglish (US)
Pages (from-to)91-107
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume47
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cell Biology
Urine
Recurrence
Cystoscopy
Signs and Symptoms
Sensitivity and Specificity

Keywords

  • Bladder
  • Bladder cancer
  • Tumor markers

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Current bladder cancer tests : Unnecessary or beneficial? / Simon, Michael A.; Lokeshwar, Vinata B; Soloway, Mark S.

In: Critical Reviews in Oncology/Hematology, Vol. 47, No. 2, 01.08.2003, p. 91-107.

Research output: Contribution to journalReview article

Simon, Michael A. ; Lokeshwar, Vinata B ; Soloway, Mark S. / Current bladder cancer tests : Unnecessary or beneficial?. In: Critical Reviews in Oncology/Hematology. 2003 ; Vol. 47, No. 2. pp. 91-107.
@article{f5f877e937a94e65881fa90689cc8e0e,
title = "Current bladder cancer tests: Unnecessary or beneficial?",
abstract = "Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.",
keywords = "Bladder, Bladder cancer, Tumor markers",
author = "Simon, {Michael A.} and Lokeshwar, {Vinata B} and Soloway, {Mark S.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1040-8428(03)00074-X",
language = "English (US)",
volume = "47",
pages = "91--107",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Current bladder cancer tests

T2 - Unnecessary or beneficial?

AU - Simon, Michael A.

AU - Lokeshwar, Vinata B

AU - Soloway, Mark S.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.

AB - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.

KW - Bladder

KW - Bladder cancer

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0041666602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041666602&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00074-X

DO - 10.1016/S1040-8428(03)00074-X

M3 - Review article

C2 - 12900004

AN - SCOPUS:0041666602

VL - 47

SP - 91

EP - 107

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -